|1.26 -0.02 (-1.56%)||12-07 15:59|
|Targets||6-month :||1.65||1-year :||1.93|
|Resists||First :||1.41||Second :||1.65|
|Supports||First :||1.2||Second :||1.07|
|MAs||MA(5) :||1.26||MA(20) :||1.21|
|MA(100) :||1.33||MA(250) :||1.92|
|MACD||MACD :||-0.1||Signal :||-0.1|
|%K %D||K(14,3) :||56.9||D(3) :||55|
|52-week||High :||3.7||Low :||1.07|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ELDN ] has closed below upper band by 21.0%. Bollinger Bands are 33.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
|If tomorrow:||Open lower||Open higher|
|High:||1.36 - 1.37||1.37 - 1.38|
|Low:||1.22 - 1.23||1.23 - 1.24|
|Close:||1.28 - 1.29||1.29 - 1.3|
Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
|Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
|Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
|Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
|Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
|Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
|Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
|Shares Out||24 (M)|
|Shares Float||18 (M)|
|Held by Insiders||6 (%)|
|Held by Institutions||29.5 (%)|
|Shares Short||66 (K)|
|Shares Short P.Month||50 (K)|
|EPS Est Next Qtrly||0|
|EPS Est This Year||0|
|EPS Est Next Year||0|
|Book Value (p.s.)||3.88|
|Profit Margin||0 %|
|Operating Margin||0 %|
|Return on Assets (ttm)||-21.8 %|
|Return on Equity (ttm)||-76.7 %|
|Qtrly Rev. Growth||0 %|
|Gross Profit (p.s.)||0|
|Sales Per Share||0|
|Qtrly Earnings Growth||0 %|
|Operating Cash Flow||-40 (M)|
|Levered Free Cash Flow||-25 (M)|
|Price to Book value||0.33|
|Price to Sales||0|
|Price to Cash Flow||-0.79|
|Dividend Pay Date||Invalid DateTime.|
|Ex-Dividend Date||Invalid DateTime.|